More studies need to be performed to determine whether XMRV poses a risk to the U.S. blood supply and whether there is any evidence that blood transfusion is linked to the development of chronic fatigue syndrome. Separate reports, published in the journal Transfusion by the HHS Blood XMRV Scientific Research Working Group and the AABB-facilitated XMRV task force, found no conclusive evidence of the latter. The studies come after a 2009 study in Science found that 67% of 101 CFS patients and 4% of healthy subjects involved had the XMRV retrovirus.

Related Summaries